Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 5, 2000, Pages 402-408

  Ellmén, Juha ^a   Werner, Dedley ^b   Hakulinen, Pasi ^a   Keiling, Roger ^c   Fargeot, Pierre ^d   Falkson, Geoffrey ^e   Bezwoda, W R ^f  

^a ORION CORPORATION   (Finland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c HÔPITAL CIVIL   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Breast cancer; Dose; Hormonal effects; Postmenopausal women; Toremifene

Indexed keywords

ESTROGEN; FOLLITROPIN; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TOREMIFENE;

ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HORMONE BLOOD LEVEL; HUMAN; LEUKORRHEA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROLOGIC DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034056230     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051009     Document Type: Article

References (33)

1. 1. Anttila M, Valavaara R, Kivinen S, Mäenpää J (1990) Pharmacokinetics of toremifene. J Steroid Biochem 36: 249-252
2. *) in postmenopausal women with advanced breast cancer: 10 mg bd. versus 20 mg bd. Br J Cancer 50: 199-205
3. 3. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for breast cancer. An overview of the randomized trials. Lancet 351: 1451-1467
4. 4. Fisher B, Costantino JP, Wickerham DL, Redmond Carol K, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N and the other National Surgical Adjuvant Breast and Bowel Project Investigators (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388
5. 5. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J (1997) A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 45: 251-262
6. 6. Gershanovich M, Hayes D, Ellmén J, Vuorinen J (1997) High dose toremifene vs. tamoxifen in postmenopausal advanced breast cancer. Oncology 11 [Suppl 4]: 29-36
7. 7. Goldhirsch A, Wood WC, Senn H-J, Glick JH, Gelber RD (1995) Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 87: 1441-1445
8. 8. Gundersen S (1990) Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study. J Steroid Biochem 36: 233-234
9. 9. Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556-2566
10. 10. Henderson IC (1991) Endocrine therapy of metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC et al. (eds) Breast diseases. Lippincott, Philadelphia, Pa. pp 559-603
11. 11. Hietanen T, Hakala T, Baltina D, Johansson R, Numminen S, Helle L, Valavaara R, Thölix E (1997) Open phase II study of high-dose toremifene as first-line therapy for advanced breast cancer. Oncology 11: 37-40
12. 12. Holli K, Joensuu H, Valavaara R, Blanco G, Kataja V, Pukkala E, for the Finnish Breast Cancer Group (1998) Toremifene vs Tamoxifen Adjuvant Trial. Abstract, 21st Annual San Antonio Breast Cancer Symposium, 283
13. 13. Homesley HD, Shemano I, Gams R, Harry DS, Hickox PG, Rebar RW, Bump RC, Mullin TJ, Colston Wentz A, Ó Toole RV, Lovelace JV, Lyden C (1993) Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. Am J Clin Oncol 16: 117-122
14. 14. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN (1995) Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13: 513-529
15. 15. Jordan VC, Dix CJ, Naylor KE, Prestwitch G, Rowsby L (1978) Nonsteroidal antiestrogens: their biological effects and potential mechanism of action. J Toxicol Environ Health 4: 363-390
16. 16. Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perilä M, Piippo I, Sundquist H, Södervall M, Toivola R (1986) A new triphenylethylene compound, Fc-1157a I Hormonal effects. Cancer Chemother Pharmacol 17: 103-108
17. 17. Kangas L, Kallio S, Blanco G, Grönroos M, Kallio S, Karjalainen A, Perilä M, Södervall M, Toivola R (1986) A new triphenylethylene compound, FC-1157a. II Antitumor effects. Cancer Chemother Pharmacol 17: 109-114
18. 18. Kangas L (1992) Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31: 143-146
19. 19. Kendall ME, Rose DP (1992) The effects of diethylstilbestrol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 114: 127-131
20. 20. Miller AB, Hoogstarten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
21. 21. Modig H, Borgström S, Nilsson I, Westman G (1990) Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication. J Steroid Biochem 36: 235-236
22. 22. Mouridsen H, Palshof T, Patterson J, Battersby L (1978) Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131-141
23. 23. Nomura Y, Tominaga T, Abe O, Izuo M, Ogawa N (1993) Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer - a comparative study by a double blind method with tamoxifen. Jpn J Cancer Chemother 20: 247-258
24. 24. Osborne CK (1991) Receptors. In: Harris J, Hellman S, Henderson I et al. (eds) Breast diseases. Lippincott, Philadelphia, Pa. pp 301-325
25. 25. Powles T, Eeles R, Ashley S, et al. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital: tamoxifen randomized chemoprevention trial. Lancet 352: 98-101
26. 26. Pyrhönen S, Valavaara R, Heikkinen M, Rissanen P, Blanco G, Nordman E, Holsti RL, Hajba A (1990) Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication. J Steroid Biochem 36: 227-228
27. 27. Pyrhönen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Blanco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A (1997) Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomized double blind, the "Nordic" phase III study. Br J Cancer 76: 270-277
28. 28. Pyrhönen S, Ellmén J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, Hayes DF (1999) Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen treatment therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat (in press)
29. 29. di Salle E, Zaccheo T, Ornati G (1990) estrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36: 203-206
30. 30. Számel I, Hindy I, Vincze B, Eckhardt S, Kangas L, Hajba A (1994) Influence of toremifene on the endocrine regulation in breast cancer patients. Eur J Cancer 30A: 154-158
31. 31. Valavaara R, Pyrhönen S, Heikkinen M, Rissanen P, Blanco G, Thölix E, Nordman E, Taskinen P, Holsti L, Hajba A (1988) Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24: 785-790
32. 32. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P on behalf of the Italian Tamoxifen Prevention Study (1998) Prevention of breast cancer with tamoxifen. Preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 352: 93-97
33. 33. WHO Adverse Reaction Dictionary. WHO Collaborating Center for International Drug Monitoring, March, 1988. Uppsala, Sweden